|
KMID : 1149120210180010016
|
|
Journal of the Korean Society for Psoriasis
2021 Volume.18 No. 1 p.16 ~ p.19
|
|
|
A Case of New-Onset Ulcerative Colitis during Secukinumab Treatment in a Patient with Psoriasis
|
|
Kim Chang-Yong
Cho Young-Ah
Kim Sung-Min
Hong Ji-Youn
Lee Yang-Won
Choe Yong-Beom
Ahn Kyu-Joong
|
|
|
Abstract
|
|
|
|
A 30-year-old male with an 8-year history of plaque-type psoriasis visited our dermatologic clinic. His past medical and family history were non-contributory to the chief complaint. Since 30 weeks of oral systemic therapy provided an inadequate response to symptoms, secukinumab administration was started. Four weeks after secukinumab injection, the patient complained of abdominal pain and diarrhea, followed gradually by bloody stool and severe abdominal pain. A colonoscopic biopsy was performed, which showed chronic active inflammation with cryptitis and crypt abscess. Ulcerative colitis (UC) was suspected to be associated with secukinumab; hence, we changed the drug to guselkumab. Twelve weeks after treatment with guselkumab, UC-associated symptoms markedly improved. In this report, we present a case of UC following secukinumab treatment for psoriasis. There have been several reports of the association between Interleukin-17 inhibitors and inflammatory bowel disease (IBD); however, clear mechanisms and causality remain unestablished. Thus, based on available evidence, the possibility of new-onset or exacerbation of underlying IBD should not be overlooked when selecting a biologic treatment for psoriatic patients.
|
|
|
KEYWORD
|
|
|
Inflammatory bowel disease, Psoriasis, Secukinumab, Ulcerative colitis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|